Form 4: Xeris Biopharma CLO Sells Shares Under 10b5-1 Plan

Xeris Biopharma Holdings, Inc.'s Chief Legal Officer, Beth Hecht, sold 16,667 shares of common stock through a pre-arranged Rule 10b5-1 trading plan.

Summary

• Beth Hecht, Chief Legal Officer and Corporate Secretary of Xeris Biopharma Holdings, Inc., reported the sale of company common stock.
• A total of 16,667 shares were sold on March 2, 2026.
• 16,567 shares were sold at a weighted average price of $6.2401 per share, with individual transaction prices ranging from $5.920 to $6.910.
• An additional 100 shares were sold at a price of $7.06 per share.
• The transactions were executed under a Rule 10b5-1 trading plan, which indicates a pre-scheduled sale.
• Following these transactions, Beth Hecht beneficially owns 1,226,507 shares of common stock.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a slightly negative event due to the insider sale, though mitigated by the 10b5-1 plan, which suggests a pre-determined financial planning move rather than a reaction to new adverse information.

Positives

• The sale was conducted under a Rule 10b5-1 trading plan, indicating a pre-scheduled transaction rather than a reaction to recent events or new material non-public information.

Negatives

• An insider sale, even under a 10b5-1 plan, reduces the insider's direct equity stake in the company, which can sometimes be perceived as a slight negative signal by the market.

Risks

• While the sale is pre-planned, significant insider selling can sometimes be perceived by the market as a lack of confidence, potentially impacting investor sentiment.

Industry Context

StockSavvy.ai notes that insider sales, particularly by high-ranking officers, are closely watched by investors. While sales under a 10b5-1 plan are generally viewed as less indicative of a negative outlook compared to open market sales, they still represent a reduction in an insider's direct financial alignment with the company's future performance. In the biopharma sector, such transactions are often scrutinized for any potential signals regarding upcoming drug approvals, clinical trial results, or strategic shifts.

Stakeholder Impact

• Shareholders may interpret the insider sale as a slight negative signal, potentially impacting investor confidence, though the 10b5-1 plan lessens this impact.

Key Dates

Recommendation

While the insider sale by the Chief Legal Officer is a reduction in her stake, the execution under a Rule 10b5-1 plan suggests a pre-planned financial decision rather than a reaction to new negative company developments. This mitigates the typical negative signal of insider selling. Without further information on company performance or strategic shifts, a 'hold' recommendation is appropriate, advising investors to monitor future filings and company news for more definitive signals.

Keywords

Xeris Biopharma Holdings, XERS, Insider Trading, Form 4, Beth Hecht, Stock Sale, 10b5-1 Plan, Biopharma, Legal Officer